The relationship between smoking cessation history and significant liver fibrosis among the population with metabolic dysfunction-associated steatotic liver disease in the United States.

<h4>Background</h4>Smoking was identified as a risk factor for the development of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). However, the association between smoking cessation history and the development of liver fibrosis remains unc...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhongtao Li, Hao Guo, Hongyu He, Shu Wang, Shufen Pei, Liang Xie
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0320573
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850186459887173632
author Zhongtao Li
Hao Guo
Hongyu He
Shu Wang
Shufen Pei
Liang Xie
author_facet Zhongtao Li
Hao Guo
Hongyu He
Shu Wang
Shufen Pei
Liang Xie
author_sort Zhongtao Li
collection DOAJ
description <h4>Background</h4>Smoking was identified as a risk factor for the development of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). However, the association between smoking cessation history and the development of liver fibrosis remains unclear. This study was intended to analyze the association between smoking cessation history and significant liver fibrosis in adult MASLD participants in the United States.<h4>Methods</h4>This study utilized data from 2643 patients with MASLD from the National Health and Nutrition Examination Survey (NHANES). Significant liver fibrosis was detected based on transient elastography measurements. According to the smoking questionnaire data, patients were categorized as non-smokers, ex-smokers and current smokers. A multivariate logistic regression analysis, adjusted for weights, was performed to investigate the relationship between smoking cessation history and the presence of significant liver fibrosis in participants with MASLD.<h4>Results</h4>A total of 2643 patients with MASLD were included in this study. Compared with non-smokers, ex-smokers had a slightly elevated risk of developing significant liver fibrosis (OR: 1.07, 95% CI: 1.02-1.13). Specifically, a positive correlation was observed between patients who quit smoking for < 20 years and significant liver fibrosis (OR: 1.07, 95% CI: 1.01-1.15). Furthermore, MASLD patients who started regularly smoking at an age of ≤ 20 years (OR: 1.09, 95% CI: 1.02-1.16) and had a smoking duration of ≥ 10 years before quitting (OR: 1.10, 95% CI: 1.02-1.18) were also highly correlated with an increased likelihood of developing significant liver fibrosis.<h4>Conclusions</h4>This study revealed that individuals with MASLD who have ceased smoking exhibit an elevated risk for significant liver fibrosis when compared to those who never smoked. It is highly emphasized that MASLD patients who quit smoking for < 20 years, started regularly smoking at an age of ≤ 20 years, and had a smoking duration of ≥ 10 years before quitting should be extremely vigilant regarding the risk of significant liver fibrosis.
format Article
id doaj-art-0afb4d5fd9874e7da8b40e4fbf73df2e
institution OA Journals
issn 1932-6203
language English
publishDate 2025-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-0afb4d5fd9874e7da8b40e4fbf73df2e2025-08-20T02:16:21ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01204e032057310.1371/journal.pone.0320573The relationship between smoking cessation history and significant liver fibrosis among the population with metabolic dysfunction-associated steatotic liver disease in the United States.Zhongtao LiHao GuoHongyu HeShu WangShufen PeiLiang Xie<h4>Background</h4>Smoking was identified as a risk factor for the development of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). However, the association between smoking cessation history and the development of liver fibrosis remains unclear. This study was intended to analyze the association between smoking cessation history and significant liver fibrosis in adult MASLD participants in the United States.<h4>Methods</h4>This study utilized data from 2643 patients with MASLD from the National Health and Nutrition Examination Survey (NHANES). Significant liver fibrosis was detected based on transient elastography measurements. According to the smoking questionnaire data, patients were categorized as non-smokers, ex-smokers and current smokers. A multivariate logistic regression analysis, adjusted for weights, was performed to investigate the relationship between smoking cessation history and the presence of significant liver fibrosis in participants with MASLD.<h4>Results</h4>A total of 2643 patients with MASLD were included in this study. Compared with non-smokers, ex-smokers had a slightly elevated risk of developing significant liver fibrosis (OR: 1.07, 95% CI: 1.02-1.13). Specifically, a positive correlation was observed between patients who quit smoking for < 20 years and significant liver fibrosis (OR: 1.07, 95% CI: 1.01-1.15). Furthermore, MASLD patients who started regularly smoking at an age of ≤ 20 years (OR: 1.09, 95% CI: 1.02-1.16) and had a smoking duration of ≥ 10 years before quitting (OR: 1.10, 95% CI: 1.02-1.18) were also highly correlated with an increased likelihood of developing significant liver fibrosis.<h4>Conclusions</h4>This study revealed that individuals with MASLD who have ceased smoking exhibit an elevated risk for significant liver fibrosis when compared to those who never smoked. It is highly emphasized that MASLD patients who quit smoking for < 20 years, started regularly smoking at an age of ≤ 20 years, and had a smoking duration of ≥ 10 years before quitting should be extremely vigilant regarding the risk of significant liver fibrosis.https://doi.org/10.1371/journal.pone.0320573
spellingShingle Zhongtao Li
Hao Guo
Hongyu He
Shu Wang
Shufen Pei
Liang Xie
The relationship between smoking cessation history and significant liver fibrosis among the population with metabolic dysfunction-associated steatotic liver disease in the United States.
PLoS ONE
title The relationship between smoking cessation history and significant liver fibrosis among the population with metabolic dysfunction-associated steatotic liver disease in the United States.
title_full The relationship between smoking cessation history and significant liver fibrosis among the population with metabolic dysfunction-associated steatotic liver disease in the United States.
title_fullStr The relationship between smoking cessation history and significant liver fibrosis among the population with metabolic dysfunction-associated steatotic liver disease in the United States.
title_full_unstemmed The relationship between smoking cessation history and significant liver fibrosis among the population with metabolic dysfunction-associated steatotic liver disease in the United States.
title_short The relationship between smoking cessation history and significant liver fibrosis among the population with metabolic dysfunction-associated steatotic liver disease in the United States.
title_sort relationship between smoking cessation history and significant liver fibrosis among the population with metabolic dysfunction associated steatotic liver disease in the united states
url https://doi.org/10.1371/journal.pone.0320573
work_keys_str_mv AT zhongtaoli therelationshipbetweensmokingcessationhistoryandsignificantliverfibrosisamongthepopulationwithmetabolicdysfunctionassociatedsteatoticliverdiseaseintheunitedstates
AT haoguo therelationshipbetweensmokingcessationhistoryandsignificantliverfibrosisamongthepopulationwithmetabolicdysfunctionassociatedsteatoticliverdiseaseintheunitedstates
AT hongyuhe therelationshipbetweensmokingcessationhistoryandsignificantliverfibrosisamongthepopulationwithmetabolicdysfunctionassociatedsteatoticliverdiseaseintheunitedstates
AT shuwang therelationshipbetweensmokingcessationhistoryandsignificantliverfibrosisamongthepopulationwithmetabolicdysfunctionassociatedsteatoticliverdiseaseintheunitedstates
AT shufenpei therelationshipbetweensmokingcessationhistoryandsignificantliverfibrosisamongthepopulationwithmetabolicdysfunctionassociatedsteatoticliverdiseaseintheunitedstates
AT liangxie therelationshipbetweensmokingcessationhistoryandsignificantliverfibrosisamongthepopulationwithmetabolicdysfunctionassociatedsteatoticliverdiseaseintheunitedstates
AT zhongtaoli relationshipbetweensmokingcessationhistoryandsignificantliverfibrosisamongthepopulationwithmetabolicdysfunctionassociatedsteatoticliverdiseaseintheunitedstates
AT haoguo relationshipbetweensmokingcessationhistoryandsignificantliverfibrosisamongthepopulationwithmetabolicdysfunctionassociatedsteatoticliverdiseaseintheunitedstates
AT hongyuhe relationshipbetweensmokingcessationhistoryandsignificantliverfibrosisamongthepopulationwithmetabolicdysfunctionassociatedsteatoticliverdiseaseintheunitedstates
AT shuwang relationshipbetweensmokingcessationhistoryandsignificantliverfibrosisamongthepopulationwithmetabolicdysfunctionassociatedsteatoticliverdiseaseintheunitedstates
AT shufenpei relationshipbetweensmokingcessationhistoryandsignificantliverfibrosisamongthepopulationwithmetabolicdysfunctionassociatedsteatoticliverdiseaseintheunitedstates
AT liangxie relationshipbetweensmokingcessationhistoryandsignificantliverfibrosisamongthepopulationwithmetabolicdysfunctionassociatedsteatoticliverdiseaseintheunitedstates